After cardiac surgery, how does nutrition fit in with risk factors?

Journal of Parenteral and Enteral Nutrition

Volumn 34, Issue 2, 2010, Pages 163-168

  Kones, Richard ^a  

^a Cardiometabolic Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTICOAGULANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

BLOOD PRESSURE REGULATION; CALCIUM METABOLISM; CORONARY ARTERY BYPASS SURGERY; CYANOCOBALAMIN DEFICIENCY; EDITORIAL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART FAILURE; HEART SURGERY; HUMAN; HYPERALDOSTERONISM; HYPOALBUMINEMIA; INSULIN RESISTANCE; LIFESTYLE; LUNG FUNCTION; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; OBESITY; OXYGENATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

DIET; HEART DISEASES; HUMANS; NUTRITIONAL SUPPORT; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 77952570337     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607109343111     Document Type: Editorial

References (60)

1. Ma Y., Li W., Olendzki B., et al. Dietary quality 1 year after diagnosis of coronary heart disease. J Am Diet Assoc. 2008 ; 108: 240-246.
2. Hartwell D., Henry J. Dietary advice for patients undergoing coronary artery bypass surgery: falling on deaf ears ? Int J Food Sci Nutr. 2003 ; 54: 37-47.
3. Pierson LM, Norton HJ, Herbert WG, et al. Recovery of self-reported functional capacity after coronary artery bypass surgery. Chest. 2003 ; 123: 1367-1374.
4. Miller LE, Pierson LM, Pierson ME, et al. Changes in bone mineral and body composition following coronary artery bypass grafting in men. Am J Cardiol. 2007 ; 99: 585-587.
5. Aquilani R., Opasich C., Verri M., et al. Is nutritional intake adequate in chronic heart failure patients ? J Am Coll Cardiol. 2003 ; 42: 1218-1223.
6. Alsafwah S., LaGuardia SP, Arroyo M., et al. Congestive heart failure is a systemic illness: a role for minerals and micronutrients. Clin Med Res. 2008 ; 5: 238-243.
7. Racca V., Castiglioni P., Ripamonti V., et al. Nutritional markers in patients after heart surgery. JPEN J Parenter Enteral Nutr. 2010 ; 34: 143-150.
8. Han E., Truesdale KP, Taber DR, et al. Impact of overweight and obesity on hospitalization: race and gender differences. Int J Obes. 2009 ; 33: 249-256.
9. Ruyun J., Gary L., Grunkemeier, AP, et al. Is obesity a risk factor for mortality in coronary artery bypass surgery ? Circulation. 2005 ; 111: 3359-3365.
10. Wigfield CH, Lindsey JD, Munoz A., et al. Is extreme obesity a risk factor for cardiac surgery? An analysis of patients with a BMI≥40. Eur J Cardiothorac Surg. 2006 ; 29: 434-440.
11. Echahidi N., Mohty D., Pibarot P., et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007 ; 116: 1213-1219.
12. Ridker PM, Danielson E., Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359: 2195-2207.
13. Gerstein HC, Miller ME, Byington RP, et al. Action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559.
14. Patel A., MacMahon S., Chalmers J., et al. ADVANCE Collaborative Group. Intensive glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572.
15. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 ; 360: 129-139.
16. Havas S. The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. Arch Intern Med. 2009 ; 169: 150-154.
17. Skyler JS, Bergenstal R., Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009 ; 119: 351-357.
18. Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998 ; 317: 703-713.
19. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 ; 364: 685-696.
20. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 ; 345: 1359-1367.
21. Wiener RS, Wiener DC, Larson RJ Benefits and risks of tight glucose control in critically ill adults. A meta-analysis. JAMA. 2008 ; 300: 933-944.
22. Balasubramanyam A. Intensive glycemic control in the intensive care unit: promises and pitfalls. J Clin Endocrinol Metab. 2009 ; 94: 416-417.
23. Nigro J., Osman N., Dart, AM, et al. Insulin resistance and atherosclerosis. Endocr Rev. 2006 ; 27: 242-259.
24. Gustafson B., Hammarstedt A., Andersson CX, et al. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2276-2283.
25. Bhatt DL Anti-inflammatory agents and antioxidants as a possible "Third Great Wave" in cardiovascular secondary prevention. Am J Cardiol. 2008 ; 101 (suppl): 4D - 13D.
26. de Ferranti S., Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008 ; 54: 945-955.
27. Cave MC, Hurt RT, Frazier TH, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract. 2008 ; 23: 16-34.
28. Mathieu P., Poirier P., Pibarot P., et al. Visceral obesity; the link among inflammation, hypertension, and cardiovascular disease. Hypertension. 2009 ; 53 (4). 577-584.
29. Collier B., Dossett LA, May AK, et al. Glucose control and the inflammatory response. Nutr Clin Pract. 2008 ; 23: 3-15.
30. Ceriello A., Ihnat MA, Thorpe JE The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications ? J Clin Endocrinol Metab. 2009 ; 94: 410-415.
31. Hlatky M. Expanding the orbit of primary prevention-moving beyond JUPITER. N Engl J Med. 2008 ; 359: 2280-2282.
32. Fuster V., Bansilal S. JUPITER strikes earth. Nat Clin Pract Cardiovasc Med. 2009 ; 6: 159.
33. Kushner I., Rzewnicki D., Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006 ; 119: 166.e17-166.e28.
34. Musunuru K., Kral BG, Blumenthal RS, et al. The use of high-sensitivity assays for c-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 ; 621-635.
35. Scheurig AC, Thorand B., Fischer B., et al. Association between the intake of vitamins and trace elements from supplements and C-reactive protein: results of the MONICA/KORA Augsburg study. Eur J Clin Nutr. 2008 ; 62: 127-137.
36. Jensen GL Inflammation as the key interface of the medical and nutrition universes: a provocative examination of the future of clinical nutrition and medicine. JPEN J Parenter Enteral Nutr. 2006 ; 30: 453-463.
37. Elliott VS Too many pills exacerbate perils of aging. American Medical News, March 26, 2007. http://www.ama-assn.org/amednews/2007/03/26/hll20326.htm Accessed February 20, 2009.
38. Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006 ; 54: 1516-1523.
39. Mallet L., Spinewine A., Huang A. Prescribing in elderly people 2: the challenge of managing drug interactions in elderly people. Lancet. 2007 ; 370: 185-191.
40. Hohl CM, Robitaille C., Lord V., et al. Emergency physician recognition of adverse drug-related events in elder patients presenting to an emergency department. Acad Emerg Med. 2005 ; 12: 197-205.
41. Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol. 2008 ; 2: 453-463.
42. Charlson ME, Isom OW Care after coronary-artery bypass surgery. N Engl J Med. 2003 ; 348: 1456-1463.
43. Eagle KA, Guyton RA, Davidoff R., et al. Coronary artery bypass graft surgery. ACC/AHA Pocket Guideline. Washington, DC and Dallas, TX: American College of Cardiology Foundation and American Heart Association Inc; 2005 :40- 43, 60-64. http://www.acc.org/qualityandscience/clinical/guidelines/CABG/index- pkt.pdf.
44. Liakopoulos OJ, Choi Y. -H, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008 ; 29: 1548-1559.
45. Shah SJ, Waters DD, Barter P., et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008 ; 51: 1938-1943.
46. Domanski M., Tian X., Fleg J., et al. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary bypass graft (post CABG) Trial. Am J Cardiol. 2008 ; 102: 1023-1027.
47. Gibbs J., Cull W., Henderson W., et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity. Arch Surg. 1999 ; 134: 36-42.
48. Rady MY, Ryan T., Starr NJ Clinical characteristics of preoperative hypoalbuminemia predict outcome of cardiovascular surgery. JPEN J Parenter Enteral Nutr. 1997 ; 21: 81-90.
49. Rapp-Kesek D., Stahle E., Karlsson TT Body mass index and albumin in the preoperative evaluation of cardiac surgery patients. Clin Nutr. 2004 ; 23: 1398-1404.
50. Boldt J., Brosch C., Rohm K., et al. Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg. 2008 ; 107: 1496-1503.
51. Allen LH How common is vitamin B-12 deficiency? Am J Clin Nutr. 2009 ; 89 (suppl): 693S - 696S.
52. Serraj K., Vogel T., Federici L., et al. Syndrome de non-dissociation de la vitamine B12 de ses proteins porteuses ou de maldigestion des cobalamines alimentaires. Press Med. 2009 ; 38: 55-62.
53. Green R. Indicators for assessing folate and vitamin B12 status and for monitoring the efficacy of intervention strategies. Food Nutr Bull. 2008 ; 29 (suppl 2). S52 - S63.
54. Ting Rz-W, Szeto CC, Chan Mh-M, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med. 2006 ; 166: 1975-1979.
55. Green R., Miller JW Vitamin B12 deficiency is the dominant nutritional cause of hyper-homocysteinemia in a folic acid-fortified population. Clin Chem Lab Med. 2005 ; 43: 1048-1051.
56. Abiles J., Abud RP, Moratalla G., et al. High prevalence of hyperhomocysteinemia in critically ill patients: vascular damage and adequate vitamin intake. Eur eJournal Clin Nutr Metab. 2008 ; 3: e240 - e245.
57. Rodionov RN, Lentz SR The homocysteine paradox. Arterioscler Throm Vasc Biol. 2008 ; 28: 1031-1033.
58. Antoniades C., Antonopoulos AS, Tousoulis D., et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009 ; 30: 6-15.
59. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med. 2009 ; 60: 39-54.
60. Schnyder G., Roffi M., Flammer Y., et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. JAMA. 2002 ; 288: 973-979.